CHEMOMAB THERAPEUTICS LTD (CMMB) Forecast, Price Target & Analyst Ratings
NASDAQ:CMMB • US16385C2035
1.98 USD
-0.02 (-1%)
At close: Mar 10, 2026
1.99 USD
+0.01 (+0.51%)
After Hours: 3/10/2026, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHEMOMAB THERAPEUTICS LTD (CMMB).
Forecast Snapshot
Consensus Price Target
$17.85
+ 801.52% Upside
Next Earnings Forecast
Release DateMay 13, 2026
PeriodQ4 / 2025
EPS Estimate-$0.32
Revenue Estimate
ChartMill Buy Consensus
85.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$17.85
Upside
+ 801.52%
From current price of $1.98 to mean target of $17.85, Based on 8 analyst forecasts
Low
$10.10
Median
$17.85
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
-33.96%
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for CMMB. The average price target is 17.85 USD. This implies a price increase of 801.52% is expected in the next year compared to the current price of 1.98.
The average price target has been revised downward by 33.96% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
CMMB was analyzed by 8 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CMMB.
In the previous month the buy percentage consensus was at a similar level.
CMMB was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-02-20 | Maxim Group | Maintains | Buy -> Buy |
| 2024-11-15 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-13 | Maxim Group | Initiate | Buy |
| 2024-05-06 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2024-03-08 | Oppenheimer | Maintains | Perform -> Perform |
| 2023-12-19 | Roth MKM | Reiterate | Buy |
| 2023-10-06 | Roth MKM | Initiate | Buy |
| 2023-06-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-04-18 | Oppenheimer | Maintains | Outperform |
| 2022-03-10 | Oppenheimer | Maintains | Outperform |
| 2021-12-07 | Aegis Capital | Initiate | Buy |
| 2021-05-26 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-05-07 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 13, 2026
PeriodQ4 / 2025
EPS Estimate-$0.32
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q50.59%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CMMB is expected to report earnings on 5/13/2026. The consensus EPS estimate for the next earnings is -0.32 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A 221.30% | N/A 280.12% | N/A 80.49% | N/A 30.64% | ||||||
| EBITDA YoY % growth | -19.27M | -10.94M 43.23% | -12.34M -12.80% | -28.47M -130.71% | -25.392M 10.81% | -14.686M 42.16% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -19.55M | -10.96M 43.94% | -12.37M -12.86% | -28.53M -130.64% | -25.459M 10.76% | -14.739M 42.11% | N/A 24.38% | N/A -104.33% | N/A -10.97% | N/A -22.77% | N/A 55.17% | N/A 423.58% | N/A 172.79% | N/A 111.35% | N/A 35.89% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -252.80 | N/A | -4.72 | -9.64 -104.24% | N/A 98.73% | -2.76 -2,154.90% | N/A 43.46% | N/A -17.65% | N/A -30.56% | N/A 97.87% | N/A -300.00% | N/A -20.00% | N/A 866.67% | N/A 58.70% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 50.59% | -0.01 98.18% | -0.01 | -0.01 | -0.01 96.77% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.164M 1.54% | -6.298M -80.61% | -6.41M -183.39% | -6.634M -259.77% | -6.746M -113.24% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
4.20%
EPS Next 5 Year
14.01%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CHEMOMAB THERAPEUTICS LTD / CMMB Forecast FAQ
What do analysts expect the price target to be for CHEMOMAB THERAPEUTICS LTD (CMMB)?
8 analysts have analysed CMMB and the average price target is 17.85 USD. This implies a price increase of 801.52% is expected in the next year compared to the current price of 1.98.
What is the next earnings date for CMMB stock?
CHEMOMAB THERAPEUTICS LTD (CMMB) will report earnings on 2026-05-13.
What are the consensus estimates for CMMB stock next earnings?
The consensus EPS estimate for the next earnings of CHEMOMAB THERAPEUTICS LTD (CMMB) is -0.32 USD and the consensus revenue estimate is 0 USD.